Higher cut-off serum procalcitonin level for sepsis diagnosis in metastatic solid tumor patients

被引：11
作者：
Aziz S.A. [1 ]
Nelwan E.J. [1 ,2 ]
Sukrisman L. [1 ,3 ]
Suhendro S. [1 ,2 ]
机构：
[1] Department of Internal Medicine, Medical Faculty University of Indonesia, Cipto Mangunkusumo General Hospital, Jalan Diponegoro No. 71, Jakarta
[2] Division of Tropical Medicine and Infectious Disease, Department of Internal Medicine, Medical Faculty University of Indonesia, Cipto Mangunkusumo General Hospital, Jalan Diponegoro No. 71, Jakarta
[3] Division of Hematology and Medical Oncology, Department of Internal Medicine, Medical Faculty University of Indonesia, Cipto Mangunkusumo General Hospital, Jalan Diponegoro No. 71, Jakarta
来源：
BMC Research Notes | / 11卷 / 1期
关键词：
Metastasis; Procalcitonin; Sepsis; Solid tumor;
D O I：
10.1186/s13104-018-3204-1
中图分类号：
学科分类号：
摘要：
Objective: The current study aimed to know procalcitonin levels in patients with metastatic tumor, and to discover the cut-off point for sepsis in this population. A cross-sectional study was conducted with patients with solid tumor. Sepsis and systemic inflammation response syndrome (SIRS) were identified using clinical, laboratory, and microbiological criteria. The cut-off point was determined using receiver operating characteristic (ROC) curve. Results: A total of 112 subjects enrolled in this study, 51% male, mean age 47.9 ± 12.47 years. Among 71 (63.4%) patients who had metastasis, 36 (32.1%) had sepsis and 6 (5.3%) experienced SIRS. In the absence of sepsis, the procalcitonin levels were significantly higher in patients with metastatic tumor compared to those without [0.25 ng/mL (0.07-1.76) vs. 0.09 ng/mL (0.03-0.54); p < 0.001]. The ROC curve showed that levels of procalcitonin for sepsis in metastatic solid tumors were in the area under curve (AUC) [0.956; CI 0.916-0.996]. Cut-off point of procalcitonin for sepsis was 1.14 ng/mL, Sn 86%, and Sp 88%. Thus, the results show that metastatic tumor affects the patients' procalcitonin level, even in the absence of sepsis. The cut-off point of procalcitonin level for diagnosing sepsis in the meta-static solid tumor was higher compared to the standard value. © 2018 The Author(s).
引用
收藏
相关论文
共 25 条
[1]  
Girmenia C., Menichetti F., Current epidemiology and prevention of infectious complications in cancer patients, Eur Oncol Haematol, 7, 4, pp. 270-277, (2011)
[2]  
Zembower T.R., Epidemiology of infections in cancer patients, Infectious Complications in Cancer Patients. Cancer Treatment and Research, pp. 43-90, (2014)
[3]  
Thirumala R., Ramaswamy M., Chawla S., Diagnosis and management of infectious complications in critically ill patients with cancer, Crit Care Clin, 26, 1, pp. 59-91, (2010)
[4]  
Namendys-Silva S.A., Gonzalez-Herrera M.O., Texcocano-Becerra J., Herrera-Gomez A., Clinical characteristics and outcomes of critically ill cancer patients with septic shock, QJM, 104, 6, pp. 505-511, (2011)
[5]  
De Montmollin E., Tandjaoui-Lambiotte Y., Legrand M., Lambert J., Mokart D., Kouatchet A., Et al., Outcomes in critically ill cancer patients with septic shock of pulmonary origin, Shock, 39, 3, pp. 250-254, (2013)
[6]  
Dasanu C.A., Trikudanathan G., Bandyopadhyay T., Lahiri B., Homsi S., Clark B.A., Tumor fever, paraneoplastic leukocytosis and necrotic liver metastases: A triad worth remembering, Conn Med, 74, 7, pp. 389-391, (2010)
[7]  
Gea-Banacloche J., Segal B.H., Infection in the cancer patient, Cancer Principles and Practice of Oncology, pp. 2262-2298, (2011)
[8]  
Meisner M., Review article update on procalcitonin measurements, Ann Lab Med, 34, pp. 263-273, (2014)
[9]  
Landskron G., De La Fuente M., Thuwajit P., Thuwajit C., Hermoso M.A., Chronic inflammation and cytokines in the tumor microenvironment, J Immunol Res, 2014, (2014)
[10]  
Meisner M., Procalcitonin-biochemistry and Clinical Diagnosis, pp. 1-97, (2010)
123